Financials in USD. Standardized financial statements.
A compact view of how TRACON Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $12.04M | $0 | $346,000 | $0 | $0 | $3.00M | $8.76M | $3.45M | $7.90M | $3.60M |
| Revenue Growth? | 0.0% | -100.0% | 0.0% | 0.0% | -100.0% | -65.7% | +153.8% | -56.4% | +119.7% | 0.0% |
| Cost of Revenue? | $14,000 | $16,000 | $14,000 | $12,000 | $22,000 | $30.46M | $19.36M | $15.24M | $20.43M | $4.85M |
| Gross Profit? | $12.03M | -$16,000 | $332,000 | -$12,000 | -$22,000 | -$27.46M | -$10.60M | -$11.79M | -$12.53M | -$1.25M |
| Gross Margin? | +99.9% | 0.0% | +96.0% | 0.0% | 0.0% | -915.3% | -121.1% | -342.0% | -158.5% | -34.9% |
| Operating Expenses? | $18.93M | $27.89M | $28.69M | $16.22M | $22.30M | $37.74M | $26.96M | $29.43M | $31.37M | $9.78M |
| Operating Income? | -$6.90M | -$27.89M | -$28.35M | -$16.22M | -$22.30M | -$34.74M | -$18.21M | -$25.98M | -$23.47M | -$6.18M |
| EBITDA? | -$6.88M | -$28.13M | -$28.33M | -$16.22M | -$22.27M | -$34.71M | -$18.17M | -$25.80M | -$23.42M | -$6.16M |
| Income Before Tax | -$3.59M | -$29.14M | -$28.67M | -$16.77M | -$22.67M | -$34.96M | -$19.10M | -$27.01M | -$24.41M | -$6.81M |
| Income Tax Expense | $0 | $177,000 | $0 | $551,000 | -$16,000 | $12,000 | $0 | $0 | $0 | $0 |
| Net Income? | -$3.59M | -$29.31M | -$28.73M | -$17.33M | -$22.66M | -$34.96M | -$19.10M | -$27.01M | -$24.41M | -$6.81M |
| EPS? | $-2.20 | $-28.02 | $-33.30 | $-38.63 | $-149.35 | $-259.47 | $-227.33 | $-426.06 | $-439.20 | $-113.70 |
| Diluted EPS? | $-2.19 | $-28.02 | $-33.30 | $-38.57 | $-149.35 | $-259.47 | $-227.33 | $-426.06 | $-439.20 | $-113.70 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality